Amicus Therapeutics
Our passion for making a difference unites us.
Our passion for making a difference unites us.
Amicus Therapeutics is a global, patient-dedicated biotechnology company founded in 2002 and headquartered in the United States. The company's slogan, "Our passion for making a difference unites us," reflects its commitment to discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. The company's name, Amicus, reflects its collaborative approach to developing medicines, incorporating the patient perspective at every step. Founded by an entrepreneur driven by a personal experience with rare disease, the company's culture is characterized by empathy, compassion, and tenacity. Amicus's mission-focused behaviors drive its performance and innovation, shaping its culture and attracting top talent. The company's recent investment of $30.00MPost-IPO Equity at 02 October 2023 was led by Blackstone Life Sciences. With a global footprint spanning over 20 countries, Amicus is committed to pushing the boundaries of medical innovation. More information about Amicus and their career opportunities can be found at www.amicusrx.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $30.00M | 1 | Blackstone Life Sciences | 02 Oct 2023 |
| Post-IPO Debt | $400.00M | 1 | Blackstone Credit | 02 Oct 2023 |
| Post-IPO Debt | $400.00M | 1 | Hayfin Capital Management | 17 Jul 2020 |
| Post-IPO Equity | $201.00M | - | 04 Jun 2019 | |
| Post-IPO Equity | $300.00M | - | 16 Feb 2018 |
No recent news or press coverage available for Amicus Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
